MX2015012818A - Mimeticos de apolipoproteina y usos de los mismos. - Google Patents

Mimeticos de apolipoproteina y usos de los mismos.

Info

Publication number
MX2015012818A
MX2015012818A MX2015012818A MX2015012818A MX2015012818A MX 2015012818 A MX2015012818 A MX 2015012818A MX 2015012818 A MX2015012818 A MX 2015012818A MX 2015012818 A MX2015012818 A MX 2015012818A MX 2015012818 A MX2015012818 A MX 2015012818A
Authority
MX
Mexico
Prior art keywords
apo
mimetic
treatment cycle
rest phase
effective amount
Prior art date
Application number
MX2015012818A
Other languages
English (en)
Inventor
G M Anantharamaiah
Dennis Goldberg
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of MX2015012818A publication Critical patent/MX2015012818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción proporciona regímenes de dosificación y métodos para tratar la ateroesclerosis con una cantidad efectiva de Apo E mimético para proporcionar efectos terapéuticos sostenidos aún después de retirar el tratamiento. Los regímenes de dosificación y métodos involucran un ciclo de tratamiento seguido de una fase de descanso donde es administrada una cantidad efectiva de Apo E mimético un sujeto durante el ciclo de tratamiento y nada de Apo E mimético durante la fase de descanso. El ciclo de tratamiento y la fase de descanso pueden variar.
MX2015012818A 2013-03-14 2014-03-14 Mimeticos de apolipoproteina y usos de los mismos. MX2015012818A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US201361834992P 2013-06-14 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Publications (1)

Publication Number Publication Date
MX2015012818A true MX2015012818A (es) 2016-05-12

Family

ID=51581312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012818A MX2015012818A (es) 2013-03-14 2014-03-14 Mimeticos de apolipoproteina y usos de los mismos.

Country Status (12)

Country Link
US (1) US20160002315A1 (es)
EP (1) EP2996706B1 (es)
JP (2) JP6570511B2 (es)
AU (2) AU2014239186B2 (es)
BR (1) BR112015022624A2 (es)
CA (1) CA2903869A1 (es)
DK (1) DK2996706T3 (es)
ES (1) ES2753381T3 (es)
IL (1) IL240787B (es)
MX (1) MX2015012818A (es)
NZ (1) NZ713291A (es)
WO (1) WO2014152776A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
MX2018009680A (es) * 2016-02-17 2018-09-10 Regeneron Pharma Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
AU2008296487A1 (en) * 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2521564B1 (en) * 2010-01-06 2016-11-16 Cognosci, Inc. Apoe peptide dimers and uses thereof
WO2016018665A1 (en) * 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Also Published As

Publication number Publication date
JP6772317B2 (ja) 2020-10-21
EP2996706A1 (en) 2016-03-23
AU2017203911B2 (en) 2019-03-07
NZ713291A (en) 2017-04-28
JP2019089834A (ja) 2019-06-13
EP2996706A4 (en) 2017-01-18
AU2017203911A1 (en) 2017-06-29
JP6570511B2 (ja) 2019-09-04
DK2996706T3 (da) 2019-10-21
BR112015022624A2 (pt) 2017-10-31
CA2903869A1 (en) 2014-09-25
EP2996706B1 (en) 2019-07-31
IL240787B (en) 2019-07-31
WO2014152776A1 (en) 2014-09-25
US20160002315A1 (en) 2016-01-07
JP2016515137A (ja) 2016-05-26
ES2753381T3 (es) 2020-04-08
AU2014239186A1 (en) 2015-10-08
IL240787A0 (en) 2015-10-29
AU2014239186B2 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
JP2012046524A5 (es)
CO7190236A2 (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
BR112015004499A2 (pt) métodos de administração de terapia de pirfenidona
IL276683A (en) Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
NZ735952A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
IN2014DN09238A (es)
MX2015011386A (es) Metodo para tratar cancer pancreatico.
MX2014005726A (es) Metodo de tratamiento de una enfermedad proliferativa.
NZ713291A (en) Apolipoprotein mimetics and uses thereof
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MY175326A (en) Product and method for treating diarrhea
MX362111B (es) Un metodo para mejorar la funcion hepatica.
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
UA69464U (uk) Спосіб лікування синдрому відміни кодтерпінової залежності у неповнолітніх
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00818A (es)

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: UAB RESEARCH FOUNDATION

FG Grant or registration